Owlstone Developing Breath Biopsy Tests for Cancer, Asthma as Pharma Services Business Expands

Mar 15, 2018

Premium

NEW YORK (360Dx) – Backed by a fresh round of financing, Owlstone Medical is intensifying its efforts to bring tests for lung cancer, colorectal cancer, and asthma to market on its Breath Biopsy platform in coming years.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Apr

26

Featured Webinar

Evaluation of a Pan-Cancer Cell-Free Assay to Meet Unmet Research Needs

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

May

01

Featured Webinar

Analytical Validation of a Liquid Biopsy Assay for High-Sensitivity Molecular Profiling

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May

08

Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

May

22

Featured Webinar

From Qualitative to Quantitative: Experiences with a cfDNA Assay in Metastatic Breast Cancer Research

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.

Main menu